Author: admin

“Anemia in Chronic Kidney Disease Market”

With improved awareness and screening, earlier diagnosis and intervention are becoming more achievable, especially with the support of emerging biomarkers and treatment guidelines. Innovative therapies such as HIF-PH inhibitors and long-acting erythropoiesis-stimulating agents (ESAs) are shaping a dynamic treatment landscape aimed at improving hemoglobin levels with fewer side effects.

DelveInsight’s “Anemia in Chronic Kidney Disease Market Report” offers an in-depth analysis of the epidemiology, disease burden, and market outlook across key geographies, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report highlights current unmet needs, late-stage pipeline therapies, market drivers and barriers, and the key players transforming patient care, making it a vital resource for healthcare stakeholders and innovators in nephrology.

Some of the Key Facts of the Anemia in Chronic Kidney Disease Market Report:

• The anemia in chronic kidney disease is expected to grow at a significant CAGR by 2034.

• In 2023, the United States recorded the highest number of prevalent Anemia in Chronic Kidney Disease (CKD) cases among the 7MM.

• The U.S. also accounted for the highest number of treated cases of Anemia in CKD during the same year.

• A higher prevalence was noted among individuals aged 60 and above compared to those under 60 in the U.S.

• Males with CKD had a 30% higher risk of developing anemia compared to females.

• Among the EU4 and the UK, Spain reported the lowest number of anemia in CKD cases in 2023.

• In Japan, anemia was one of the most frequently documented outcomes, with prevalence rates ranging from 0% to 95%, depending on CKD severity and dialysis status.

• In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome.

• In March 2025, scPharmaceuticals received FDA approval for a supplemental new drug application (sNDA) for Furoscix (furosemide injection). This approval expands the drug’s use to treat edema in patients with chronic kidney disease (CKD), marking a significant advancement in scPharmaceuticals’ portfolio for cardiorenal conditions.

• In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA’s acceptance of the supplemental new drug application in July 2024.

• In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk.

• In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a PDUFA target action date set for June 28, 2025. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis.

• Leading companies in the anemia in chronic kidney disease market include Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others.

• Emerging therapies in the anemia in chronic kidney disease market include DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others.

• The rising prevalence of anemia in chronic kidney disease, along with continuous advancements in therapeutic options, is fueling the demand for more effective treatment approaches.

To know in detail about the anemia in chronic kidney disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Anemia In Chronic Kidney Disease Market Forecast

Anemia in Chronic Kidney Disease Overview

Anemia is a frequent and serious complication of Chronic Kidney Disease (CKD), arising as kidney function declines and the body’s ability to produce adequate erythropoietin—a hormone essential for red blood cell production, diminishes. CKD impairs the kidneys’ filtering ability, leading to the accumulation of waste and fluids, which further contributes to the onset of anemia.

The condition becomes increasingly prevalent in advanced stages of CKD. In the United States, over 37 million adults are estimated to have CKD, and more than one in seven individuals with CKD also suffer from anemia. The risk intensifies as kidney function deteriorates, with nearly all individuals at end-stage kidney failure (when kidney function drops below 15%) experiencing anemia.

Certain populations are more susceptible: individuals with CKD and diabetes are at higher risk of developing anemia earlier and in more severe forms. Additionally, people over the age of 60 are more likely to be affected. The progression of CKD-related anemia is typically gradual and may remain asymptomatic in its early stages, making early detection and management crucial for improving patient outcomes.

Get a free sample of the anemia in chronic kidney disease market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market

Anemia in Chronic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Anemia in Chronic Kidney Disease Epidemiology Segmentation:

The anemia in chronic kidney disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Prevalent Cases of Chronic Kidney Disease

• Diagnosed Cases of Anemia in Chronic Kidney Disease

• Age-Specific Prevalent Cases of Anemia in Chronic Kidney Disease

• Total Prevalent Cases of Anemia in Chronic Kidney Disease

• Total Prevalent Cases of Anemia in Different Stages of Chronic Kidney Disease

• Treatable Cases of Anemia in Chronic Kidney Disease

Download the report to understand which factors are driving anemia in chronic kidney disease epidemiology trends @ Anemia In Chronic Kidney Disease Epidemiology Forecast

Anemia in Chronic Kidney Disease Drugs Uptake and Pipeline Development Activities

The anemia in chronic kidney disease drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the anemia in chronic kidney disease market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the anemia in chronic kidney disease pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Anemia in Chronic Kidney Disease Market Strengths

• The availability of novel oral treatment options, such as daprodustat, offers more convenient and effective routes of administration for patients.

• Active research and ongoing clinical trials are enhancing the understanding of the disease and driving innovation in therapeutic strategies.

Anemia in Chronic Kidney Disease Market Weaknesses

• Patients often struggle to recognize or differentiate the symptoms of anemia from CKD or other related conditions, leading to underreporting.

• Healthcare providers, particularly in non-dialysis settings, frequently under-monitor hemoglobin levels and iron stores, resulting in delayed or suboptimal treatment initiation.

Scope of the Anemia in Chronic Kidney Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Anemia In Chronic Kidney Disease Companies: GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others.

• Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others.

• Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia in chronic kidney disease, currently marketed, and anemia in chronic kidney disease emerging therapies

• Anemia In Chronic Kidney Disease Market Dynamics: Anemia in chronic kidney disease market drivers and anemia in chronic kidney disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Anemia In Chronic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Anemia In Chronic Kidney Disease Market Access and Reimbursement

To learn more about the key players and advancements in the anemia in chronic kidney disease treatment landscape, visit the Anemia In Chronic Kidney Disease Market Analysis Report

Table of Contents

1. Anemia In Chronic Kidney Disease Market Report Introduction

2. Executive Summary for Anemia In Chronic Kidney Disease

3. SWOT analysis of Anemia In Chronic Kidney Disease

4. Anemia In Chronic Kidney Disease Patient Share (%) Overview at a Glance

5. Anemia In Chronic Kidney Disease Market Overview at a Glance

6. Anemia In Chronic Kidney Disease Disease Background and Overview

7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Anemia In Chronic Kidney Disease

9. Anemia In Chronic Kidney Disease Current Treatment and Medical Practices

10. Anemia In Chronic Kidney Disease Unmet Needs

11. Anemia In Chronic Kidney Disease Emerging Therapies

12. Anemia In Chronic Kidney Disease Market Outlook

13. Country-Wise Anemia In Chronic Kidney Disease Market Analysis (2020–2034)

14. Anemia In Chronic Kidney Disease Market Access and Reimbursement of Therapies

15. Anemia In Chronic Kidney Disease Market Drivers

16. Anemia In Chronic Kidney Disease Market Barriers

17. Anemia In Chronic Kidney Disease Appendix

18. Anemia In Chronic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anemia in Chronic Kidney Disease Market Set for Significant Growth and Innovation by 2034 | Says DelveInsight

“Venous Leg Ulcer Market”

DelveInsight’s “Venous Leg Ulcer Market Report” provides a comprehensive analysis of the VLU landscape, including detailed historical and projected epidemiological data across major markets such as the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report also outlines the current standard of care, unmet needs, evolving treatment patterns, and the pipeline of emerging therapies targeting wound healing and venous restoration.

With the introduction of advanced wound care solutions, compression technologies, and bioengineered skin substitutes, the VLU market is poised for significant innovation and expansion. This report offers critical insights into market dynamics, key growth drivers, and the pharmaceutical and medical device companies leading the charge in transforming VLU care. It serves as a valuable resource for industry stakeholders, investors, researchers, and clinicians aiming to navigate the evolving VLU treatment ecosystem.

Some of the Key Facts of the Venous Leg Ulcer Market Report:

• The venous leg ulcer market is expected to grow at a significant CAGR by 2034.

• In 2023, the US had the highest number of diagnosed VLU cases among the 7MM, with numbers expected to rise by 2034.

• VLU affected more women than men in the US, a trend likely to continue during the forecast period.

• Older adults in the US showed the highest age-specific prevalence of VLU.

• Among EU4 and the UK, Germany had the most VLU cases, while Spain had the fewest.

• Overall, men were less affected by VLU than women in 2023.

• VLU treatment includes wound care, compression therapy, medications, and advanced therapies.

• Surgical options and adjunctive treatments like HBOT and NPWT are used for chronic cases.

• In May 2025, MediWound Ltd. (Nasdaq: MDWD) announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis draws on data from the company’s Phase II ChronEx clinical trial, which evaluated the safety and efficacy of EscharEx® in treating venous leg ulcers (VLUs) compared to collagenase ointment (SANTYL®), currently the only FDA-cleared enzymatic debridement agent available for dermal ulcers.

• In February 2025, MediWound Ltd. (Nasdaq: MDWD) announced the launch of VALUE, a pivotal global Phase III trial to evaluate EscharEx® for treating venous leg ulcers (VLUs).

• In December 2024, Merakris Therapeutics announced the start of enrollment for Part 2 of its Phase 2 trial (NCT04647240) testing Dermacyte® Amniotic Wound Care Liquid. This randomized, double-blind, placebo-controlled study will enroll patients at approximately 10 US sites, with dosing beginning promptly. The injectable biologic is designed to aid healing in venous leg ulcers (VLUs).

• In September 2024, Merakris Therapeutics announced FDA approval to begin Part 2 of its Phase II clinical trial (NCT04647240) for Dermacyte® Amniotic Wound Care Liquid, a subcutaneous biological injection, after reviewing initial study results.

• In February 2024, MediWound announced positive results from a head-to-head comparison of EscharEx versus SANTYL within the ChronEx Phase II Randomized Controlled Study. The results demonstrated the superiority of EscharEx, a bromelain-based gel, over SANTYL, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU).

• Leading companies in the venous leg ulcer market include Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure Limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma, RHEACELL, and others.

• Emerging acute venous leg ulcer drugs include rhGM-CSF, ENERGI-F703, EscharEx, Aurase® Wound Gel, TR 987, Ropocamptide, NLP328, APZ 2, and others.

• The increasing prevalence of venous leg ulcers and ongoing advancements in therapeutic options are driving the demand for more effective treatment approaches.

To know in detail about the venous leg ulcer market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Venous Leg Ulcer Market Forecast

Venous Leg Ulcer Overview

Venous Leg Ulcers (VLUs) are chronic, non-healing wounds that typically occur on the lower legs due to chronic venous insufficiency (CVI). They represent the most common type of leg ulcer and are a major health burden, especially in aging populations. VLUs are primarily caused by elevated venous pressure resulting from valve dysfunction in the leg veins, leading to blood pooling, inflammation, and eventual skin breakdown.

Clinically, VLUs present as shallow, irregularly shaped wounds, often located around the medial malleolus, with symptoms such as swelling, aching, and skin discoloration. They are often recurrent and slow to heal, significantly impairing patients’ quality of life.

Management of VLUs involves a multifaceted approach, including compression therapy (the cornerstone of treatment), wound care, pharmacologic agents, and in some cases, surgical or endovascular interventions. Despite available treatments, healing can be slow, and recurrence rates remain high, emphasizing the need for innovative therapies and personalized care.

Recent advancements in biologics, enzymatic debridement agents, and adjunctive treatments such as negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBOT) are reshaping the treatment landscape. With growing awareness and better diagnostic tools, early intervention and improved outcomes are becoming increasingly achievable.

Get a free sample of the Venous Leg Ulcer market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/venous-leg-ulcer-market

Venous Leg Ulcer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Venous Leg Ulcer Epidemiology Segmentation:

The venous leg ulcer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Prevalent Cases of VLU

• Gender-Specific Cases of VLU

• VLU cases by severity/ chronicity of wound

• Total Diagnosed Cases of VLU

• Age-Specific Cases of VLU

• Treated cases of VLU

Download the report to understand which factors are driving venous leg ulcer epidemiology trends @ Venous Leg Ulcer Epidemiology Forecast

Venous Leg Ulcer Drugs Uptake and Pipeline Development Activities

The venous leg ulcer drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the venous leg ulcer market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the venous leg ulcer pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Venous Leg Ulcer Market Strengths

• The increasing incidence of chronic venous insufficiency, particularly among the elderly, is driving demand for effective VLU treatments.

• Innovations such as bioengineered dressings, negative pressure wound therapy (NPWT), and digital health tools are enhancing treatment efficacy and patient outcomes.

Venous Leg Ulcer Market Weaknesses

• High Treatment Costs: Advanced therapies and wound care products can be expensive, limiting accessibility, especially in low-income regions.

• Limited Awareness and Diagnosis: A lack of awareness among patients and healthcare providers can lead to delayed diagnosis and suboptimal treatment, hindering market growth.

Scope of the Venous Leg Ulcer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Venous Leg Ulcer Companies: Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure Limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma, RHEACELL, and others.

• Key Venous Leg Ulcer Therapies: rhGM-CSF, ENERGI-F703, EscharEx, Aurase® Wound Gel, TR 987, Ropocamptide, NLP328, APZ 2, and others.

• Venous Leg Ulcer Therapeutic Assessment: Venous leg ulcer, currently marketed, and Venous Leg Ulcer emerging therapies

• Venous Leg Ulcer Market Dynamics: Venous leg ulcer market drivers and Venous Leg Ulcer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Venous Leg Ulcer Unmet Needs, KOL’s views, Analyst’s views, Venous Leg Ulcer Market Access and Reimbursement

To learn more about the key players and advancements in the venous leg ulcer treatment landscape, visit the Venous Leg Ulcer Market Analysis Report

Table of Contents

1. Venous Leg Ulcer Market Report Introduction

2. Executive Summary for Venous Leg Ulcer

3. SWOT analysis of Venous Leg Ulcer

4. Venous Leg Ulcer Patient Share (%) Overview at a Glance

5. Venous Leg Ulcer Market Overview at a Glance

6. Venous Leg Ulcer Disease Background and Overview

7. Venous Leg Ulcer Epidemiology and Patient Population

8. Country-Specific Patient Population of Venous Leg Ulcer

9. Venous Leg Ulcer Current Treatment and Medical Practices

10. Venous Leg Ulcer Unmet Needs

11. Venous Leg Ulcer Emerging Therapies

12. Venous Leg Ulcer Market Outlook

13. Country-Wise Venous Leg Ulcer Market Analysis (2020–2034)

14. Venous Leg Ulcer Market Access and Reimbursement of Therapies

15. Venous Leg Ulcer Market Drivers

16. Venous Leg Ulcer Market Barriers

17. Venous Leg Ulcer Appendix

18. Venous Leg Ulcer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Venous Leg Ulcer Market Set to Evolve with Advancements in Wound Care and Rising Patient Burden by 2034 | Says DelveInsight

“Acute Myocardial Infarction Market”

The “Acute Myocardial Infarction Market Report” by DelveInsight offers a robust analysis of market size, treatment algorithms, and unmet needs across the 7MM, providing stakeholders with actionable insights to navigate a highly competitive and evolving cardiovascular space.

Some of the Key Facts of the Acute Myocardial Infarction Market Report:

• The AMI market in the 7MM is valued at USD 1.6 billion in 2023, with expected strong growth.

• In 2023, the U.S. had ~823K incident AMI cases, projected to rise by 2034.

• LODOCO, FDA-approved by AGEPHA Pharma, is the first treatment targeting residual inflammatory risk in cardiovascular disease.

• NSTEMI cases (~607K) outnumbered STEMI cases in the U.S. in 2023.

• In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the FDA. This recognition highlights PMcardio’s innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention.

• In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FLYRCADO (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women.

• Emerging acute myocardial infarction drugs include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.

• Leading companies in the acute myocardial infarction market include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.

To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Acute Myocardial Infarction Market Forecast

Acute Myocardial Infarction Overview

Acute Myocardial Infarction (AMI) refers to the death of heart muscle tissue due to the sudden blockage of a coronary artery. Common symptoms include chest pain, shortness of breath, nausea, and sweating. Diagnosis is based on electrocardiogram (ECG) findings and cardiac biomarkers. Treatment typically involves antiplatelet and anticoagulant medications, nitrates, beta-blockers, statins, and timely reperfusion therapies. In ST-segment elevation myocardial infarction (STEMI), emergency reperfusion is achieved through fibrinolytics, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). In non-ST-segment elevation myocardial infarction (NSTEMI), PCI or CABG is also used.

AMI remains a leading cause of mortality in developed nations and is classified into two main types: STEMI and NSTEMI. While unstable angina shares similarities with NSTEMI, it does not show elevated cardiac biomarkers.

Get a free sample of the acute myocardial infarction market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market

Acute Myocardial Infarction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Myocardial Infarction Epidemiology Segmentation:

The Acute Myocardial Infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Incident Cases of AMI

• Type-Specific Incident Cases of AMI

• Gender-Specific Incident Cases of AMI

Download the report to understand which factors are driving acute myocardial infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast

Acute Myocardial Infarction Drugs Uptake, and Pipeline Development Activities

The acute myocardial infarction drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the acute myocardial infarction market or expected to be launched during the study period. The analysis covers the acute myocardial infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the acute myocardial infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Myocardial Infarction Market Strengths

• Strong pipeline with innovative therapies targeting inflammation, thrombosis, and cardiac repair.

• High disease burden and awareness ensure steady demand for treatment and care.

Acute Myocardial Infarction Market Weaknesses

• High treatment costs limit access in low- and middle-income regions.

• Delayed diagnosis and limited emergency care affect outcomes in underserved areas.

Scope of the Acute Myocardial Infarction Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.

• Key Acute Myocardial Infarction Companies: Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.

• Acute Myocardial Infarction Therapeutic Assessment: Acute myocardial infarction, currently marketed, and acute myocardial infarction emerging therapies

• Acute Myocardial Infarction Market Dynamics: Acute myocardial infarction market drivers and Acute Myocardial Infarction market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Acute Myocardial Infarction Unmet Needs, KOL’s views, Analyst’s views, Acute Myocardial Infarction Market Access and Reimbursement

To learn more about the key players and advancements in the acute myocardial infarction treatment landscape, visit the Acute Myocardial Infarction Market Analysis Report

Table of Contents

1. Acute Myocardial Infarction Market Report Introduction

2. Executive Summary for Acute Myocardial Infarction

3. SWOT analysis of Acute Myocardial Infarction

4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance

5. Acute Myocardial Infarction Market Overview at a Glance

6. Acute Myocardial Infarction Disease Background and Overview

7. Acute Myocardial Infarction Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Myocardial Infarction

9. Acute Myocardial Infarction Current Treatment and Medical Practices

10. Acute Myocardial Infarction Unmet Needs

11. Acute Myocardial Infarction Emerging Therapies

12. Acute Myocardial Infarction Market Outlook

13. Country-Wise Acute Myocardial Infarction Market Analysis (2020–2034)

14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies

15. Acute Myocardial Infarction Market Drivers

16. Acute Myocardial Infarction Market Barriers

17. Acute Myocardial Infarction Appendix

18. Acute Myocardial Infarction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Myocardial Infarction Market to Evolve with Novel Therapies and Strategic Advancements by 2034 | Forecasts DelveInsight

DelveInsight’s “Restrictive Cardiomyopathy Market Report” provides a thorough analysis of RCM, including historical and forecasted epidemiological data, along with trends in the treatment landscape across key regions such as the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report also highlights emerging therapies, market growth drivers, and the leading companies shaping the RCM market, offering valuable insights for stakeholders in the healthcare sector.

Some of the Key Facts of the Restrictive Cardiomyopathy Market Report:

• In 2023, the restrictive cardiomyopathy market size across the 7MM was approximately ~USD 27 million, with strong growth expected through 2034.

• There were around 73K diagnosed prevalent cases in the 7MM, including 36K in the US.

• In the US, key treatments, RASIs (ACEi/ARBs), beta-blockers, diuretics, mineralocorticoid receptor antagonists, and antiarrhythmics, generated nearly USD 18 million.

• RASIs held the largest restrictive cardiomyopathy market share across the 7MM, contributing about ~USD 11 million in 2023.

• In March 2025, Alnylam Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase III trial, evaluating vutrisiran for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a patient population representative of today’s cases.

• In March 2025, Intellia Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for treating transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM).

• In March 2025, Alnylam Pharmaceuticals announced FDA approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA (vutrisiran), for treating the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits.

• In February 2025, BridgeBio Pharma received European approval for acoramidis, a drug treating cardiomyopathy caused by transthyretin amyloidosis (ATTR), a rare metabolic condition. The approval strengthens BridgeBio’s position to compete with Pfizer’s blockbuster drug, currently the standard treatment for ATTR.

• In November 2024, the FDA approved BridgeBio’s oral drug, Attruby, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and life-threatening heart condition. This marks the first new treatment in a market largely dominated by Pfizer’s Vyndaqel.

• Leading companies in the restrictive cardiomyopathy market include GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others.

• The rising prevalence of restrictive cardiomyopathy, coupled with ongoing advancements in therapeutic options, is driving the demand for more effective treatment approaches.

To know in detail about the restrictive cardiomyopathy market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Restrictive Cardiomyopathy Market Forecast

Restrictive Cardiomyopathy Overview

Restrictive cardiomyopathy is a cardiac disorder characterized by increased stiffness of the heart muscle, which limits the heart’s ability to fill properly during the relaxation phase of the cardiac cycle. This impaired filling reduces cardiac output and can ultimately lead to heart failure.

The condition can arise from a variety of causes, including infiltrative disorders such as amyloidosis, sarcoidosis, and hemochromatosis, where abnormal substances build up in the heart tissue. Additional causes include storage diseases, endomyocardial fibrosis, prior exposure to radiation therapy, genetic predispositions, and systemic illnesses like connective tissue disorders.

Patients with restrictive cardiomyopathy often present with symptoms associated with heart failure. These include shortness of breath, particularly during exertion or when lying flat, fatigue, weakness, swelling in the lower extremities and abdomen, abdominal discomfort due to liver congestion, palpitations, and irregular heart rhythms. Over time, these symptoms may intensify as the heart’s pumping function becomes increasingly compromised.

Get a free sample of the restrictive cardiomyopathy market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/restrictive-cardiomyopathy-market

Restrictive Cardiomyopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Restrictive Cardiomyopathy Epidemiology Segmentation:

The restrictive cardiomyopathy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Diagnosed Prevalent Cases of Restrictive Cardiomyopathy

• Gender-specific Diagnosed Prevalent Cases of Restrictive Cardiomyopathy

Download the report to understand which factors are driving restrictive cardiomyopathy epidemiology trends @ Restrictive Cardiomyopathy Epidemiology Forecast

Restrictive Cardiomyopathy Drugs Uptake and Pipeline Development Activities

The restrictive cardiomyopathy drug uptake section analyzes the adoption trends of recently launched therapies and those anticipated to enter the market during the forecast period. It examines drug-wise uptake, patient share by therapy, and individual drug sales to provide a clear picture of market dynamics.

The therapeutics assessment section highlights the drugs showing the fastest uptake, exploring the underlying factors driving their adoption. It also offers a comparative analysis based on market share, enabling a deeper understanding of their competitive positioning.

Additionally, the report offers a comprehensive overview of pipeline development activities in the restrictive cardiomyopathy landscape. It includes insights into therapeutic candidates across various clinical stages and profiles key companies driving innovation. The analysis also covers recent strategic developments such as collaborations, mergers and acquisitions, licensing agreements, and patent activity related to emerging therapies.

Restrictive Cardiomyopathy Market Strengths

• Rising awareness and better diagnostic tools are leading to earlier and more accurate detection of RCM.

• Progress in genetic and molecular research is driving the development of targeted and innovative treatments.

Restrictive Cardiomyopathy Market Weaknesses

• The market lacks approved therapies specifically for RCM, limiting effective treatment options.

• Low prevalence restricts commercial interest and makes large clinical trials difficult.

Scope of the Restrictive Cardiomyopathy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Restrictive Cardiomyopathy Companies: GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others.

• Restrictive Cardiomyopathy Therapeutic Assessment: Restrictive cardiomyopathy, currently marketed and restrictive cardiomyopathy emerging therapies

• Restrictive Cardiomyopathy Market Dynamics: Restrictive cardiomyopathy market drivers and Restrictive Cardiomyopathy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Restrictive Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Restrictive Cardiomyopathy Market Access and Reimbursement

To learn more about the key players and advancements in the restrictive cardiomyopathy treatment landscape, visit the Restrictive Cardiomyopathy Market Analysis Report

Table of Contents

1. Restrictive Cardiomyopathy Market Report Introduction

2. Executive Summary for Restrictive Cardiomyopathy

3. SWOT analysis of Restrictive Cardiomyopathy

4. Restrictive Cardiomyopathy Patient Share (%) Overview at a Glance

5. Restrictive Cardiomyopathy Market Overview at a Glance

6. Restrictive Cardiomyopathy Disease Background and Overview

7. Restrictive Cardiomyopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Restrictive Cardiomyopathy

9. Restrictive Cardiomyopathy Current Treatment and Medical Practices

10. Restrictive Cardiomyopathy Unmet Needs

11. Restrictive Cardiomyopathy Emerging Therapies

12. Restrictive Cardiomyopathy Market Outlook

13. Country-Wise Restrictive Cardiomyopathy Market Analysis (2020–2034)

14. Restrictive Cardiomyopathy Market Access and Reimbursement of Therapies

15. Restrictive Cardiomyopathy Market Drivers

16. Restrictive Cardiomyopathy Market Barriers

17. Restrictive Cardiomyopathy Appendix

18. Restrictive Cardiomyopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Restrictive Cardiomyopathy Market Set for Transformative Developments and Rising Demand by 2034 | Says DelveInsight

“Coagulation Factor Deficiency Market”

DelveInsight’s “Coagulation Factor Deficiency Market Report” delivers detailed analysis of market dynamics, historical and forecasted epidemiology, and emerging therapies across the 7MM (US, EU5, and Japan), highlighting key players and trends driving this rare disease segment.

Some of the Key Facts of the Coagulation Factor Deficiency Market Report:

• In 2023, the coagulation factor deficiency market in the 7MM was valued at approximately USD 13.5 billion.

• The US led the market, contributing around USD 7.2 billion.

• There were about 105K prevalent cases across the 7MM, with the US accounting for nearly 34K.

• Hemophilia A was the most common subtype among all coagulation factor deficiencies.

• Marketed drugs for coagulation factor deficiency include ESPEROCT (Novo Nordisk), JIVI (Bayer), and WILATE (Octapharma).

• In March 2025, the FDA approved QFITLIA (fitusiran) for routine prophylaxis to reduce bleeding episodes in patients (12+) with hemophilia A or B, with or without factor VIII or IX inhibitors.

• In December 2024, Novo announced that the FDA approved concizumab, its tissue factor pathway inhibitor (TFPI) antagonist, as a once-daily treatment to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B with inhibitors.

• In October 2024, Novo Nordisk received support from European regulators for the approval of its anti-TFPI antibody, Alhemo (concizumab), as a preventive treatment for hemophilia. The company stated that, if approved, this therapy would provide the first subcutaneous prophylactic treatment to be administered once daily for individuals with hemophilia A or B who have inhibitors.

• In March 2024, ReciBioPharm signed a collaboration agreement with GeneVentiv Therapeutics, a preclinical gene therapy company, to advance the development of an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, and reportedly the first to treat hemophilia patients with inhibitors.

• Emerging coagulation factor deficiency drugs include Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.

• Leading companies in the coagulation factor deficiency market include Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.

• The rising incidence of coagulation factor deficiencies, along with ongoing advancements in treatment options, is driving the demand for more effective therapies for these conditions.

To know in detail about the coagulation factor deficiency market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Coagulation Factor Deficiency Market Forecast

Coagulation Factor Deficiency Overview

Coagulation factor deficiencies, also referred to as bleeding or clotting disorders, are a group of inherited or acquired conditions caused by the absence or dysfunction of specific proteins that are essential for blood clotting. These proteins, known as coagulation factors, are vital for halting bleeding by forming clots to close off damaged blood vessels.

There are 13 coagulation factors, each numbered from I to XIII, that work together in a complex process to maintain hemostasis. Deficiencies in any of these factors can lead to abnormal bleeding, with severity varying based on the specific factor affected and the extent of the deficiency.

Get a free sample of the coagulation factor deficiency market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market

Coagulation Factor Deficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Coagulation Factor Deficiency Epidemiology Segmentation:

The coagulation factor deficiency epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total diagnosed prevalent cases

• Factor-specific prevalent cases

Download the report to understand which factors are driving coagulation factor deficiency epidemiology trends @ Coagulation Factor Deficiency Epidemiology Forecast

Coagulation Factor Deficiency Drugs Uptake, and Pipeline Development Activities

The coagulation factor deficiency drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the coagulation factor deficiency market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the coagulation factor deficiency pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Coagulation Factor Deficiency Market Strengths

• New gene therapies for coagulation factor deficiencies, like Hemophilia A and B, offer potential long-term or curative solutions.

• Better awareness and diagnostic tools are enabling earlier detection and more effective management.

Coagulation Factor Deficiency Market Weaknesses

•Many therapies, particularly gene therapies, remain expensive, limiting accessibility.

• Advanced therapies are not widely accessible in lower-income regions due to cost and healthcare limitations.

Scope of the Coagulation Factor Deficiency Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Coagulation Factor Deficiency Therapies: Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.

• Key Coagulation Factor Deficiency Companies: Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.

• Coagulation Factor Deficiency Therapeutic Assessment: Coagulation factor deficiency, currently marketed, and coagulation factor deficiency emerging therapies

• Coagulation Factor Deficiency Market Dynamics: Coagulation factor deficiency market drivers and Coagulation Factor Deficiency market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Coagulation Factor Deficiency Unmet Needs, KOL’s views, Analyst’s views, Coagulation Factor Deficiency Market Access and Reimbursement

To learn more about the key players and advancements in the coagulation factor deficiency treatment landscape, visit the Coagulation Factor Deficiency Market Analysis Report

Table of Contents

1. Coagulation Factor Deficiency Market Report Introduction

2. Executive Summary for Coagulation Factor Deficiency

3. SWOT analysis of Coagulation Factor Deficiency

4. Coagulation Factor Deficiency Patient Share (%) Overview at a Glance

5. Coagulation Factor Deficiency Market Overview at a Glance

6. Coagulation Factor Deficiency Disease Background and Overview

7. Coagulation Factor Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Coagulation Factor Deficiency

9. Coagulation Factor Deficiency Current Treatment and Medical Practices

10. Coagulation Factor Deficiency Unmet Needs

11. Coagulation Factor Deficiency Emerging Therapies

12. Coagulation Factor Deficiency Market Outlook

13. Country-Wise Coagulation Factor Deficiency Market Analysis (2020–2034)

14. Coagulation Factor Deficiency Market Access and Reimbursement of Therapies

15. Coagulation Factor Deficiency Market Drivers

16. Coagulation Factor Deficiency Market Barriers

17. Coagulation Factor Deficiency Appendix

18. Coagulation Factor Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Coagulation Factor Deficiency Market to Witness Significant Innovation and Growth by 2034 | Predicts DelveInsight